Skip to main content
. 2019 Apr 12;10(6):575–582. doi: 10.3892/mco.2019.1843

Figure 3.

Figure 3.

Overall survival and disease-free survival of unmatched patients treated with neoadjuvant chemoradiotherapy plus surgery (Group A) vs. surgery alone (Group B). They did not significantly differ in overall survival, but disease-free survival was significantly higher in Group A than in Group B (P<0.05).